表紙
市場調查報告書

次世代生物製劑市場預測 (∼2029年):抗體醫藥技術、胰島素、生長激素、重組凝血因子、再生醫療之收益預測和研發趨勢

Next-Generation Biologics Market Forecast to 2029: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

出版商 Visiongain Ltd 商品編碼 927172
出版日期 內容資訊 英文 296 Pages
商品交期: 最快1-2個工作天內
價格
次世代生物製劑市場預測 (∼2029年):抗體醫藥技術、胰島素、生長激素、重組凝血因子、再生醫療之收益預測和研發趨勢 Next-Generation Biologics Market Forecast to 2029: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine
出版日期: 2019年11月29日內容資訊: 英文 296 Pages
簡介

推估全球次世代生物製劑市場於2018年達32億美元規模。預估在預測期間前半期將以19.8%的CAGR成長。

本報告研究全球次世代抗體治療市場,系統性彙整市場概要、按區分的市場預測、區域/國家的收益預測、主要企業等情報。

第1章 報告概要

第2章 次世代生物製劑簡介

  • 生物製劑開發簡史
  • 具潛力次世代生物製劑

第3章 全球次世代生物製劑市場:展望與預測

  • 全球次世代生物製劑市場
  • 次世代生物製劑市場

第4章 次世代生物製劑的區域次市場預測

  • 國家次市場預測
  • 重要市場的疾病發病率增加
  • 主要國家次市場的次世代生物製劑核准
  • 北美次世代生物製劑市場
  • 歐洲次世代生物製劑市場
  • 亞太地區次世代生物製劑市場
  • 其他地區 (RoW) 次世代生物製劑市場

第5章 次世代抗體:次市場展望

  • 改善抗體治療藥的策略
  • 次世代抗體治療藥次市場
  • 次世代抗體治療藥次市場預測
  • 抗體藥物複合體 (ADC) 次市場
  • 工程抗體次市場
  • 雙特異性抗體次市場

第6章 抗體片段和新抗體樣蛋白質 (ALP) :商業潛力

  • 次世代抗體片段
  • 抗體片段和ALP次市場
  • 次世代抗體片段展望
  • ALP次市場
  • 次世代免疫毒素會改變市場嗎?

第7章 次世代胰島素次市場展望

  • 次世代胰島素開發策略
  • 次世代胰島素次市場
  • 口服胰島素次市場
  • 超速效型胰島素次市場
  • 超長效型胰島素次市場

第8章 其他次世代重組蛋白質預測

  • 其他次世代重組蛋白質定義
  • 次世代重組凝血因子
  • 次世代生長激素

第9章 再生醫療:商業展望

  • 再生醫療次市場
  • 再生醫療次市場:收益預測
  • 幹細胞療法次市場
  • 組織工程展望
  • 基因治療次市場

第10章 次世代生物製劑:產業趨勢

  • 次世代生物製劑:市場強項
  • 次世代生物製劑:市場弱點
  • 次世代生物製劑市場:STEP分析
  • 次世代生物製劑:開發趨勢
  • 次世代生物製劑:製造課題和機會
  • 次世代生物製劑的商業化
  • 次世代生物製劑開發的合作

第11章 次世代生物製劑主要製造商

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Sanofi
  • Abbvie
  • Amgen
  • Novo Nordisk
  • Seattle Genetics

第12章 結論

  • 次世代生物製劑市場至2029年將強勁成長
  • 次世代抗體開發領導市場
  • 新治療法推動次世代生物製劑需求
  • 主要國家市場
  • 次世代生物製劑開發和商業化仍存留課題

附錄

目錄
Product Code: PHA0621

The global next-generation biologics market is estimated to have reached $3.2bn in 2018. The market is expected to grow at a CAGR of 19.8% in the first half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 296-page report you will receive 181 charts - all unavailable elsewhere.

The 296-page report provides clear detailed insight into the next-generation biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Next-Generation Biologics Market forecast to 2029

Revenue forecasts for the Next-Generation Biologics Market by Sector to 2029:

  • Regenerative Medicine: Stem Cell Therapies, Tissue

Engineering, Gene Therapies

  • Next-Generation Antibody Therapies: ADC, Engineered

Antibodies, Bispecific Antibodies

  • Next-Generation Antibody Fragments & ALPs
  • Next-Generation Insulin: Oral Insulin, Ultra- Rapid

Acting Insulin, Ultra-Long Acting Insulin

  • Next-Generation Growth Hormones
  • Next-Generation Coagulating Factors
  • Others

Revenue forecasts for the Next-Generation Biologics Market Forecast by Region to 2029:

North America:

  • U.S.
  • Canada

Europe:

  • Germany
  • UK
  • France
  • Italy
  • Spain

Asia-Pacific:

  • Japan
  • China
  • India

RoW

  • Brazil
  • Mexico
  • Russia
  • South Africa

Profiles of the selected leading companies:

  • AbbVie
  • Amgen
  • Eli Lilly
  • GSK
  • Novo Nordisk
  • Roche/ Genentech
  • Sanofi Aventis
  • Seattle Genetics

The report also includes a STEP Analysis of the Next-Generation Biologics market.

Key questions answered by this report:

  • How is the next-generation biologics therapies market evolving?
  • What is driving and restraining the next-generation biologics market?
  • What are the market shares of segments of the overall next-generation biologics market in 2018?
  • How will each next-generation biologics segment grow over the forecast period and how much revenue will these submarkets account for by 2029?
  • How will the market shares for next-generation biologics therapies submarkets develop to 2029?
  • Which therapies can succeed and what are their revenue potentials?
  • What will be the main sales drivers for the overall market to 2029?
  • How will political and regulatory factors influence the regional markets and other submarkets?
  • How will the market shares of the regional markets change by 2029 and which geographical region will lead the market by 2029?
  • How will the industry evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation biologics Market. You find data, trends and predictions.

Buy our report today Next-Generation Biologics Market Forecast to 2029: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Overview of the Next-Generation Biologics Market
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to Next-Generation Biologics

  • 2.1 Brief History of Biological Drug Development
    • 2.1.1 Limitations of Present-Generation Biological Drugs
  • 2.2 The Promise of Next-Generation Biologics
    • 2.2.1 Defining Next-Generation Biologics
      • 2.2.1.1 A Definition of Regenerative Medicine
      • 2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies

3. World Next-Generation Biologics Market: Outlook and Forecast to 2029

  • 3.1 The Next-Generation Biologics Market 2018
    • 3.1.1 Development of the Next-Generation Biologics Market 2009-2016
    • 3.1.2 Rising Demand for Biological Therapies
    • 3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2018
    • 3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
    • 3.1.5 Leading Companies in the Next-Generation Biologics Market 2018
  • 3.2 The Next-Generation Biologics Market 2019-2029
    • 3.2.1 Growth Drivers for Biological Drug Revenues 2019-2029
    • 3.2.2 Global Next-Generation Biologics Market Forecast 2019-2029
    • 3.2.3 Product Launches in All Sectors to Drive Market Growth 2019-2029
    • 3.2.4 Next-Generation Biologics: Market Restraints 2019-2029
    • 3.2.5 Rising Market Shares for Next-Generation Insulins 2019-2029

4. Regional Submarkets for Next-Generation Biologics Forecast to 2029

  • 4.1 National Submarket Forecasts 2019-2029
    • 4.1.1 How Will National Submarket Shares Change to 2029?
  • 4.2 Rising Disease Incidence in Important Markets 2019-2029
  • 4.3 Approval of Next-Generation Biologics in Leading National Submarkets
  • 4.4 North America Next-Generation Biologics Market 2019-2029
    • 4.4.1 US Will be the Largest Submarket for Next-Generation Biologics 2019-2029
    • 4.4.2 Canada Next-Generation Biologics Market 2019-2029
  • 4.5 European Next-Generation Biologics Market 2019-2029
    • 4.5.1 Regenerative Medicine Development in the EU
    • 4.5.2 Market Access for Next-Generation Biologics in the EU
    • 4.5.3 Germany: Submarket Forecast 2019-2029
    • 4.5.4 UK: Submarket Forecast 2019-2029
    • 4.5.5 France: Submarket Forecast 2019-2029
    • 4.5.6 Italy and Spain: Submarket Forecasts 2019-2029
  • 4.6 Asia Pacific Next-Generation Biologics 2019-2029
    • 4.6.1 Japan Next-Generation Biologics Market 2019-2029
      • 4.6.1.1 National Expertise in Stem Cell Research
      • 4.6.1.2 Japanese Submarket Forecast 2019-2029
    • 4.6.2 Chinese Submarket Forecast 2019-2029
    • 4.6.3 Indian Submarket Forecast 2019-2029
  • 4.7 RoW Next-Generation Biologics Markets 2019-2029
    • 4.7.1 Brazil Next-Generation Biologics Market 2019-2029
    • 4.7.2 Mexico Next-Generation Biologics Market 2019-2029
    • 4.7.3 Russia Next-Generation Biologics Market 2019-2029
    • 4.7.4 South Africa Next-Generation Biologics Market 2019-2029

5. Next-Generation Antibodies: Submarket Outlooks to 2029

  • 5.1 Strategies for Improving Antibody Therapies
    • 5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
    • 5.1.2 Engineering Antibodies for Improved Potency
    • 5.1.3 Bispecific Antibodies
  • 5.2 Next-Generation Antibody Therapy Submarket
  • 5.3 Next-Generation Antibody Therapy Submarket 2019-2029
    • 5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2019-2029
    • 5.3.2 Blockbuster Potential Will Drive Growth to 2029: Kadcyla, Adcetris and Cosentyx
    • 5.3.3 Next-Generation Antibodies: Submarket Restraints 2019-2029
  • 5.4 Antibody-Drug Conjugates (ADC) Submarket 2019-2029
    • 5.4.1 Antibody-Drug Conjugates Submarket Forecast 2019-2029
      • 5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2019-2029
    • 5.4.2 What Will Drive Growth for ACDs to 2029
    • 5.4.3 A Long Pipeline of ADCs in Clinical Development
      • 5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
      • 5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
      • 5.4.3.3 IMGN853 (Immunogen): Phase III for Ovarian Cancer
      • 5.4.3.4 SGN-CD33A (Seattle Genetics): Phase III for Acute myeloid leukemia
      • 5.4.3.5 Rova-T (Abbvie): Phase III for SCLC
      • 5.4.3.6 CDX-011: Potential for Accelerated Approval in Breast Cancer
  • 5.5 Engineered Antibodies Submarket 2019-2029
    • 5.5.1 Engineered Antibodies Submarket Forecast 2019-2029
      • 5.5.1.1 Gazvya Will Lead the Submarket by 2029
    • 5.5.2 Portfolio Management to Drive Growth 2019-2029
    • 5.5.3 Engineered Antibodies Pipeline 2018
      • 5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
  • 5.6 Bispecific Antibodies Submarket 2019-2029
    • 5.6.1 Bispecific Antibodies Submarket Forecast 2019-2029
    • 5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2019-2029
    • 5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2018
      • 5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody

6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential to 2029

  • 6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
    • 6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
    • 6.1.2 There are Advantages to Using Fragments and Novel Scaffolds
  • 6.2 Antibody Fragment and ALP Submarket 2019-2029
    • 6.2.1 Antibody Fragment and ALP Submarket Forecast 2019-2029
    • 6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs
    • 6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2029
  • 6.3 Outlook for Next-Generation Antibody Fragments 2019-2029
    • 6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2019-2029
    • 6.3.2 One Platform Leads the Pipeline in 2018
      • 6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
      • 6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
  • 6.4 The Antibody-Like Protein Submarket 2019-2029
    • 6.4.1 Antibody-Like Protein Submarket Forecast 2019-2029
    • 6.4.2 Four ALPs in Clinical Development in 2018
      • 6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
  • 6.5 Will Next-Generation Immunotoxins Change the Market to 2029?
    • 6.5.1 Challenges with First Generation Immunotoxins
    • 6.5.2 Fusion Protein Conjugates: Pipeline 2018
      • 6.5.2.1 Moxetumomab Pasudotox
    • 6.5.3 Humanised Immunotoxins
      • 6.5.3.1 Using Granzyme B in Immunotoxins
      • 6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins

7. Next-Generation Insulin Submarket: Outlook to 2029

  • 7.1 Strategies for Next-Generation Insulin Development
    • 7.1.1 Reformulating Insulin for Convenient Administration
      • 7.1.1.1 Oral Insulin
      • 7.1.1.2 Inhaled Insulin
      • 7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
  • 7.2 Next-Generation Insulin Submarket 2019-2029
    • 7.2.1 Tresiba: Approved in the EU and Japan
      • 7.2.1.1 Tresiba: Revenue Forecast 2019-2029
  • 7.3 Next-Generation Insulin Submarket 2018-2029
    • 7.3.1 Next-Generation Insulin Submarket Forecast 2018-2029
    • 7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2019-2029
    • 7.3.3 Next-Generation Insulin Submarket Restraints 2019-2029
      • 7.3.3.1 Biosimilar Insulins are Available Since 2015
  • 7.4 Oral Insulin Submarket 2019-2029
    • 7.4.1 Oral Insulin Submarket Forecast 2019-2029
    • 7.4.2 Oral Insulin: Submarket Drivers and Restraints 2019-2029
    • 7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2018
      • 7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
      • 7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
      • 7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
      • 7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
      • 7.4.3.5 Novo Nordisk: NN-1953
  • 7.5 Ultra-Rapid Acting Insulin Submarket 2019-2029
    • 7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2019-2029
      • 7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2029?
    • 7.5.2 Other Submarket Drivers and Restraints 2019-2029
    • 7.5.3 Ultra-Rapid Acting Insulin Pipeline 2018
      • 7.5.3.1 FlAsp (Novo Nordisk)
      • 7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
      • 7.5.3.3 Halozyme Therapeutics
      • 7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
      • 7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
      • 7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
  • 7.6 Ultra-Long Acting Insulin Submarket 2019-2029
    • 7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2019-2029
    • 7.6.2 Revenue Growth Driven by Uptake of Tresiba
    • 7.6.3 Ultra-Long Acting Insulin Pipeline 2018
      • 7.6.3.1 Toujeo: Sanofi's Next-Generation Insulin Analogue
      • 7.6.3.2 LAPS-Insulin

8. Next-Generation Developments for Other Recombinant Proteins Forecast to 2029

  • 8.1 Defining Next-Generation for Other Recombinant Protein Sectors
    • 8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2019-2029
      • 8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2019-2029
    • 8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
      • 8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2017
  • 8.2 Next-Generation Recombinant Coagulation Factors 2019-2029
    • 8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2019-2029
    • 8.2.2 Submarket Drivers and Restraints 2019-2029
    • 8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2019-2029
      • 8.2.3.1 Fused Factors: Biogen Idec's Eloctate and Alprolix
      • 8.2.3.2 Baxter's BAX 855
      • 8.2.3.3 CSL Behring's rlX-FP: Albumin-Bound Coagulation Factors
      • 8.2.3.4 Bayer's BAY94-9027
      • 8.2.3.5 Novo Nordisk's N8-GP for Haemophilia A
      • 8.2.3.6 Novo Nordisk's N9-GP for Haemophilia B
    • 8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
  • 8.3 Next-Generation Growth Hormones 2019-2029
    • 8.3.1 Next-Generation Growth Hormone Submarket Forecast 2019-2029
    • 8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2019-2029
    • 8.3.3 Long-Acting Growth Hormones
      • 8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
      • 8.3.3.2 Prolor Biotech/OPKO Health
      • 8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
      • 8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
    • 8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
      • 8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin

9. Regenerative Medicine: Commercial Outlook to 2029

  • 9.1 The Regenerative Medicine Submarket in 2018
    • 9.1.1 Defining Regenerative Medicine
  • 9.2 The Regenerative Medicine Submarket: Revenue Projections 2019-2029
    • 9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2019-2029
  • 9.3 The Stem Cell Therapies Submarket 2019-2029
    • 9.3.1 Prochymal (Mesoblast) for GvHD
      • 9.3.1.1 The Future for Prochymal: Approval in Crohn's Disease?
      • 9.3.1.2 A Note on Stem Cell Transplants
    • 9.3.2 Stem Cell Therapies Submarket Forecast 2019-2029
    • 9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2019-2029
      • 9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
    • 9.3.4 Stem Cell Therapies Late-Stage Pipeline 2018
      • 9.3.4.1 Cx601 (TiGenix)
      • 9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
      • 9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
      • 9.3.4.4 StemEx (Gamida Cell)
  • 9.4 Outlook for Tissue Engineering 2019-2029
    • 9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
      • 9.4.1.1 Apligraf Leads the Wound Repair Submarket
      • 9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014
    • 9.4.2 Tissue Engineering Submarket Forecast 2019-2029
    • 9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2019-2029
    • 9.4.4 Future Developments in Cartilage Repair: Pipeline 2018
    • 9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
      • 9.4.5.1 Engineered Skin
      • 9.4.5.2 Engineered Veins
      • 9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
  • 9.5 The Gene Therapies Submarket 2019-2029
    • 9.5.1 Glybera Approved and Set for Launch in the EU
    • 9.5.2 Gene Therapies Submarket: Revenue Projections 2019-2029
    • 9.5.3 Glybera's Approval Driving Submarket Growth Since 2014
    • 9.5.4 There are More Than Five Gene Therapies in Late-Stage Development
      • 9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
      • 9.5.4.2 TVEC (Amgen)
      • 9.5.4.3 Generx (Cardium Therapeutics)
      • 9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy

10. Next-Generation Biologics: Industry Trends to 2029

  • 10.1 Next-Generation Biologics: Market Strengths 2018
  • 10.2 Next-Generation Biologics: Market Weakness 2018
  • 10.3 The Next-Generation Biologics Market: STEP Analysis 2019-2029
    • 10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
      • 10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
      • 10.3.1.2 Next-Generation Biologic Development in Emerging Markets
    • 10.3.2 Technological Developments 2019-2029
    • 10.3.3 Economic Pressures 2019-2029
      • 10.3.3.1 High Drug Costs and Healthcare Spending
      • 10.3.3.2 Limited Commercial Potential in Emerging Markets?
    • 10.3.4 Political Issues: Regulatory Developments 2019-2029
  • 10.4 Next-Generation Biologics: Development Trends 2019-2029
    • 10.4.1 Improving Patient Convenience
    • 10.4.2 Sustained Release Biologics: Pegylation and Beyond
    • 10.4.3 Therapeutic Focus for Next-Generation Biologics
    • 10.4.4 Next-Generation Biologics as Personalised Medicine
  • 10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
    • 10.5.1 Contract Manufacturers Invest to Follow Development Trends
  • 10.6 Commercialising Next-Generation Biologics
    • 10.6.1 Product Lifecycle Management for First Generation Biologics
    • 10.6.2 Proving Benefit in Next-Generation Products
    • 10.6.3 Biosimilars as a Challenger 2019-2029
  • 10.7 Partnering for Next-Generation Biologic Development
    • 10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
    • 10.7.2 Most Development Platforms Stem from Small Biotechs

11. Leading Manufacturers of Next-Generation Biologics

  • 11.1 Eli Lilly and Company
    • 11.1.1 Financial Overview
    • 11.1.2 Key Developments
    • 11.1.3 SWOT Analysis
  • 11.2 F. Hoffmann-La Roche Ltd
    • 11.2.1 Financials
    • 11.2.2 Key Developments
    • 11.2.3 SWOT Analysis
  • 11.3 GlaxoSmithKline plc
    • 11.3.1 Financial Overview
    • 11.3.1 Key Developments
    • 11.3.2 SWOT Analysis
  • 11.4 Sanofi
    • 11.4.1 Financial Overview
    • 11.4.2 Key Developments
  • 11.5 Abbvie
    • 11.5.1 Financial Overview
    • 11.5.2 Key Developments
    • 11.5.3 SWOT Analysis
  • 11.6 Amgen
    • 11.6.1 Financial Overview
    • 11.6.2 Recent Key Developments
    • 11.6.3 SWOT Analysis
  • 11.7 Novo Nordisk
    • 11.7.1 Financial Overview
    • 11.7.2 Key Developments
    • 11.7.3 SWOT Analysis
  • 11.8 Seattle Genetics
    • 11.8.1 Financial Overview
    • 11.8.2 SWOT Analysis

12. Conclusions from Our Research and Analysis

  • 12.1 The Next-Generation Biologics Market Will Grow Strongly to 2029
  • 12.2 Next-Generation Antibody Development Will Lead the Market
  • 12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
  • 12.4 Leading National Markets
  • 12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997
  • Table 3.1 Top Ten Bestselling Prescription Pharmaceuticals: Revenues ($bn), 2017
  • Table 3.2 Next-Generation Biologics Market: Revenues ($bn) & Market Share (%) by Sector, 2018
  • Table 3.3 Biological Drugs Market: Drivers and Restraints, 2019-2029
  • Table 3.4 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%) by Sector, 2019-2029
  • Table 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2019, 2024 and 2029
  • Table 4.1 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2018
  • Table 4.2 National Incidence and Prevalence of Leading Indications Treated with Biologics (millions of patients), 2016
  • Table 4.3 Main Approval Dates for Next-Generation Biologics in Leading National Submarkets, 2003-2013
  • Table 4.4 Next-Generation Biologics Submarkets in the North America Nations: Revenues ($bn) & Market Share (%) 2018
  • Table 4.5 North America Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.6 North America Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.7 North America Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.8 North America Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.9 North America Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.10 US Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.11 Next-Generation Biologics Approval
  • Table 4.12 Canada Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.13 Next-Generation Biologics Submarkets in the EU Nations: Revenues ($bn) & Market Share (%) 2018
  • Table 4.14 Europe Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.15 Europe Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.16 Europe Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.17 Europe Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.18 Europe Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.19 German Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.20 UK Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.21 France Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.22 Italian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.23 Spanish Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%) 2019-2029
  • Table 4.24 Next-Generation Biologics Submarkets in the Asia Pacific Nations: Revenues ($bn) & Market Share (%) 2018
  • Table 4.25 Asia Pacific Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.26 Asia Pacific Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.27 Asia Pacific Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.28 Asia Pacific Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.29 Asia Pacific Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.30 Biosimilars Approved and Marketed in Japan, 2018
  • Table 4.31 Japanese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.32 Chinese Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.33 Indian Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.34 Next-Generation Biologics Submarkets in RoW Nations: Revenues ($bn) & Market Share (%) 2018
  • Table 4.35 RoW Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.36 RoW Regenerative Medicine Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.37 RoW Next-Generation Antibody Therapies Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.38 RoW Next-Generation Antibody Fragments & ALPs Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.39 RoW Next-Generation Insulin Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.40 Brazil Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.41 Mexico Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.42 Russia Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 4.43 South Africa Next-Generation Biologics Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 5.1 Monoclonal Antibodies Submarket: Leading Drug Revenues ($bn), 2017
  • Table 5.2 Next-Generation Antibodies Submarket: Approved Drug Revenues ($bn), 2018
  • Table 5.3 Selected Clinical and Pre-Clinical ADC Platforms, 2018
  • Table 5.4 Selected Clinical and Pre-Clinical Engineered Antibody Platforms, 2018
  • Table 5.5 Next-Generation Antibodies Submarket: Revenues by Sector ($bn) & Market Share (%), 2018
  • Table 5.6 Next-Generation Antibodies Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%), & CAGR (%), by Sector, 2018-2029
  • Table 5.7 Next-Generation Antibodies Submarket: Drivers and Restraints, 2019-2029
  • Table 5.8 Antibody Drug Conjugates Submarket: Revenues ($bn) and Submarket Shares (%) by Drug, 2018
  • Table 5.9 Antibody-Drug Conjugates Submarket Forecast ($bn), AGR (%), & CAGR (%), 2019-2029
  • Table 5.10 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2018-2029
  • Table 5.11 Antibody-Drug Conjugates Submarket: Drivers and Restraints, 2019-2029
  • Table 5.12 Selected Antibody-Drug Conjugates in Phase III Development, 2018
  • Table 5.13 Selected Antibody-Drug Conjugates in Phase II Development, 2018
  • Table 5.14 Selected Antibody-Drug Conjugates in Phase I Development, 2018
  • Table 5.15 Engineered Antibodies Submarket Forecast ($bn), 2019-2029
  • Table 5.16 Gazyva/Gazyvaro: Revenue Forecast ($bn), 2018-2029
  • Table 5.17 Engineered Antibodies Submarket: Drivers and Restraints, 2019-2029
  • Table 5.18 Selected Engineered Antibodies in Phase II and III Development, 2018
  • Table 5.19 Bispecific Antibodies Submarket Forecast ($bn), 2019-2029
  • Table 5.20 Bispecific Antibodies Submarket: Drivers and Restraints, 2019-2029
  • Table 5.21 Bispecific Antibodies in Phase I and II Development, 2018
  • Table 6.1 Selected Next-Generation Antibody Fragment Platforms, 2018
  • Table 6.2 Selected Antibody-Like Protein Platforms, 2018
  • Table 6.3 Next-Generation Antibody Fragment and ALP Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) & CAGR (%), by Sector, 2019-2029
  • Table 6.4 Next-Generation Antibody Fragment and ALP Submarket: Drivers and Restraints, 2019-2029
  • Table 6.5 Next-Generation Antibody Fragment Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 6.6 Next-Generation Antibody Fragment Submarket: Clinical Pipeline, 2018
  • Table 6.7 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2018-2029
  • Table 6.8 Next-Generation Antibody-Like Protein Submarket: Clinical Pipeline, 2018
  • Table 7.1 Tresiba: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 7.2 Next-Generation Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2019-2029
  • Table 7.3 Next-Generation Insulin Submarket: Drivers and Restraints, 2019-2029
  • Table 7.4 Diabetes: Prevalence and Proportion of Population Affected, 2016
  • Table 7.5 Leading Insulin Analogues: US and EU Patent Expiries, 2013-2019
  • Table 7.5 Oral Insulin Submarket Forecast ($bn), & CAGR (%) 2019-2029
  • Table 7.6 Oral Insulin Submarket: Drivers and Restraints, 2019-2029
  • Table 7.7 Oral Insulin: Selected Pre-Clinical and Clinical-Stage Pipeline, 2018
  • Table 7.8 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2019-2029
  • Table 7.9 Ultra-Rapid Acting Insulin Submarket: Drivers and Restraints, 2019-2029
  • Table 7.10 Ultra-Rapid Acting Insulin: Pre-Clinical and Clinical-Stage Pipeline, 2018
  • Table 7.11 Afrezza: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 7.12 Ultra-Long Acting Insulin Forecast ($bn) AGR (%) & CAGR (%), 2019-2029
  • Table 7.13 Ultra-Long Acting Insulin Submarket: Drivers and Restraints, 2019-2029
  • Table 7.14 Selected Ultra-Long Acting Insulin: Clinical-Stage Pipeline, 2018
  • Table 8.1 Plegridy: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 8.2 Recombinant Coagulation Factor Half-Lives and Target Populations, 2018
  • Table 8.3 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 8.4 Next-Generation Recombinant Coagulation Factors Submarket: Drivers and Restraints, 2019-2029
  • Table 8.5 Long-Acting Recombinant Factors VIII and IX in Late-Stage Clinical Development, 2018
  • Table 8.6 Eloctate: Revenue Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 8.7 Alprolix: Revenue Forecast ($bn), 2019-2029
  • Table 8.8 Next-Generation Growth Hormones Submarket Forecast ($bn), 2019-2029
  • Table 8.9 Next-Generation Growth Hormones Submarket: Drivers and Restraints, 2019-2029
  • Table 8.10 Selected Next-Generation Growth Hormones in Clinical Development, 2018
  • Table 9.1 Regenerative Medicine Submarket: Revenues by Sector ($bn) & Submarket Share (%) 2018
  • Table 9.2 Regenerative Medicine Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn), AGR (%) and CAGR (%) by Sector, 2018-2029
  • Table 9.3 Regenerative Medicine Submarket: Drivers and Restraints, 2019-2029
  • Table 9.4 Stem Cell Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 9.5 Stem Cell Therapies Submarket: Drivers and Restraints, 2019-2029
  • Table 9.6 Selected Stem Cell Therapies in Phase II and III Clinical Trials, 2018
  • Table 9.7 Selected Stem Cell Therapies in Phase I/II Development, 2018
  • Table 9.8 Tissue Engineering Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 9.9 Tissue Engineering Submarket: Drivers and Restraints, 2019-2029
  • Table 9.10 Gene Therapies Submarket Forecast ($bn), AGR (%) & CAGR (%), 2018-2029
  • Table 9.11 Gene Therapies Submarket: Drivers and Restraints, 2019-2029
  • Table 9.12 Gene Therapies in Phase II and III Clinical Trials, 2018
  • Table 10.1 Next-Generation Biologics: STEP Analysis, 2019-2029
  • Table 10.2 Selected CMO Investments in Next-Generation Biologics, to 2018
  • Table 12.1 Next-Generation Biologics Market: Submarket Forecasts ($bn) and Market Shares (%), 2018, 2024 and 2029
  • Table 12.2 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2018

List of Figures

  • Figure 1.1 Next-Generation Biologic Market Segmentation, 2017
  • Figure 3.1 Next-Generation Biologics: Market Shares (%) by Sector, 2018
  • Figure 3.2 Next-Generation Biologics Market: Revenue Forecast ($bn), 2019-2029
  • Figure 3.3 Next-Generation Biologics: Market Drivers, 2018-2028
  • Figure 3.4 Next-Generation Biologics: Market Restraints, 2018-2029
  • Figure 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2018-2029
  • Figure 4.1 Next-Generation Biologics: Market Shares (%) by Country, 2019
  • Figure 4.2 Next-Generation Biologics: Market Revenue ($bn) by Country, 2018-2029
  • Figure 4.3 Next-Generation Biologics: Market Shares (%) by Country, 2018-2029
  • Figure 4.4 North America Region: Next-Generation Biologics Submarket Shares (%), 2018-2029
  • Figure 4.5 US Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.6 Canada Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.7 EU Region: Next-Generation Biologics Submarket Shares (%), 2018-2029
  • Figure 4.8 German Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.9 UK Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.10 French Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.11 Italian Next-Generation Biologics Submarket Forecast ($bn), 2019-2029
  • Figure 4.12 Spanish Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.13 Asia Pacific Region: Next-Generation Biologics Submarket Shares (%), 2018-2029
  • Figure 4.14 Japanese Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.15 Chinese Next-Generation Biologics Submarket Forecast ($bn) &AGR (%), 2019-2029
  • Figure 4.16 Indian Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.17 RoW Region: Next-Generation Biologics Submarket Shares (%), 2018-2029
  • Figure 4.18 Brazil Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.19 Mexico Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.20 Russia Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 4.21 South Africa Next-Generation Biologics Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 5.1 Next-Generation Antibodies: Submarket Shares (%) by Sector, 2018-2029
  • Figure 5.2 Next-Generation Antibodies Submarket Forecast ($bn), 2018-2029
  • Figure 5.3 Antibody-Drug Conjugates: Submarket Shares (%) by Drug, 2018
  • Figure 5.4 Kadcyla Revenue Forecasts ($bn) & AGR (%), 2019-2029
  • Figure 5.5 Adcetris: Revenue Forecasts ($bn) & AGR (%), 2019-2029
  • Figure 6.1 Next-Generation Antibody Fragment and ALP Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 6.2 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2018-2029
  • Figure 6.3 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2018-2029
  • Figure 7.1 Tresiba: Revenue Forecast ($bn), & AGR (%), 2019-2029
  • Figure 7.2 Next-Generation Insulin Submarket Revenue Forecast ($bn), 2019-2029
  • Figure 7.3 Diabetes: Proportion of Population Affected, 2016
  • Figure 7.4 Oral Insulin Submarket Forecast ($bn), 2019-2029
  • Figure 7.5 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2019-2029
  • Figure 7.6 Afrezza: Revenue Forecast ($bn), 2019-2029
  • Figure 7.7 Ultra-Long Acting Insulin Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 8.1 Plegridy: Revenue Forecast ($bn) & AGR (%), 2018-2029
  • Figure 8.2 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 8.3 Eloctate: Revenue Forecast ($bn), 2019-2029
  • Figure 8.4 Alprolix: Revenue Forecast ($bn), 2019-2029
  • Figure 8.5 Next-Generation Growth Hormones Submarket Forecast ($bn), 2019-2029
  • Figure 9.1 Regenerative Medicine: Submarket Shares (%) by Sector, 2018-2029
  • Figure 9.2 Regenerative Medicine Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 9.3 Stem Cell Therapies Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 9.4 Tissue Engineering Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 9.5 Gene Therapies Submarket Forecast ($bn) & AGR (%), 2018-2029
  • Figure 10.1 Big Pharma Partnering Opportunities for Next-Generation Biologics Development, 2018
  • Figure 11.1 Eli Lilly and Company Revenue ($mn), 2014-2017
  • Figure 11.2 Roche Revenue ($bn) & AGR (%) 2016-2018
  • Figure 11.3 GSK Revenue ($mn), 2014-2017
  • Figure 11.4 Sanofi Revenue ($bn) & AGR (%) 2014-2017
  • Figure 11.5 AbbVie Revenue ($bn) & AGR (%) 2014-2017
  • Figure 11.6 Amgen Revenue ($bn) & AGR (%) 2015-2018
  • Figure 11.7 Novo Nordisk Revenue ($mn) & AGR (%) 2015-2018
  • Figure 11.8 Revenue ($bn) & AGR (%) 2014-2018
  • Figure 12.1 Next-Generation Biologics Market: Revenue Forecast ($bn), 2018, 2024, & 2029

List of Companies Mentioned in the Report

  • 3SBio
  • Aastrom Biosciences (now Vericel Corporation)
  • AbbVie
  • Abcam
  • Ablynx
  • ADC Therapeutics
  • Adnexus (part of Bristol-Myers Squibb)
  • Adocia
  • Advanced Cell Technology (now Ocata Therapeutics)
  • Advantagene
  • Affibody
  • Agensys (now part of Astellas Pharma)
  • Alcon (part of Novartis)
  • Alexion Pharmaceuticals
  • Alfacell (now Tamir Biotechnology)
  • Alkermes
  • Allergan
  • Allozyne
  • Ambrx
  • Amgen
  • AMRI
  • AnGes
  • Applied Genetic Technologies (AGTC)
  • Ark Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Athersys
  • Avita Medical
  • Baxter International
  • Bayer Healthcare
  • Belrose Pharma
  • Benda Pharmaceutical
  • Biocad
  • BioCancell Therapeutics
  • Biocon
  • Biodel
  • Biogen Idec
  • Bioheart
  • BioMarin Pharmaceutical
  • Biopartners (part of Bioton)
  • Biotest Pharmaceuticals
  • Bioton
  • BioVex Group (part of Amgen)
  • BioWa (part of Kyowa Hakko Kirin)
  • bluebird bio
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Capricor Therapeutics
  • Cardio3 BioSciences
  • Cardium Therapeutics
  • Catalent Pharma Solutions
  • Celgene
  • Celladon
  • CellCoTec
  • Celldex Therapeutics
  • Cellerant Therapeutics
  • Cellular Dynamics International (CDI)
  • Cephalon (part of Teva)
  • CEPiA (part of Sanofi)
  • Ceregene
  • Chatham Therapeutics
  • Chiesi Farmaceutici
  • Chugai (part of Roche)
  • Civitas Therapeutics
  • Clayton Biotechnologies
  • Cold Genesys
  • Concortis
  • Covagen
  • Crescendo Biologics
  • Critical Pharmaceuticals
  • CSL Behring
  • CytoMedix
  • Cytori Therapeutics
  • Dance Biopharm
  • Delenex Therapeutics
  • Depuy Mitek (part of J&J)
  • Diabetology
  • Diasome Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Dyax
  • Eddingpharm
  • EGEN
  • Eisai
  • Elan Pharmaceuticals (now part of Perrigo Company)
  • Eli Lilly
  • Emisphere
  • Enzon Pharmaceuticals
  • EnzymeRx
  • Epitomics (part of Abcam)
  • ESBATech (part of Novartis)
  • Flamel Technologies
  • Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
  • Fuji Pharma
  • Fujifilm Diosynth Biotechnologies
  • Gamida Cell
  • Genentech (part of Roche)
  • Generex Biotechnology
  • Genmab
  • Genzyme (part of Sanofi)
  • Geron
  • GlaxoSmithKline (GSK)
  • GlycoExpress
  • Glycotope
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Health Canada
  • Hikma Pharmaceuticals
  • Histogenics
  • Humacyte
  • Human Stem Cells Institute (HSCI)
  • Igenica
  • ImmunoGen
  • Immunomedics
  • Innovent Biologics
  • Integra LifeSciences
  • Introgen Therapeutics
  • Jain Foundation
  • JCR Pharmaceuticals
  • Johnson & Johnson (J&J)
  • Juventas Therapeutics
  • Karolinska Institute
  • Kyowa Hakko Kirin
  • LG Life Sciences
  • LifeCell
  • Lonza
  • Loyola University
  • MacroGenics
  • MannKind
  • MedImmune (part of AstraZeneca)
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Merrimack Pharmaceuticals
  • Merrion Pharmaceuticals
  • Mersana Therapeutics
  • Mesoblast
  • Micromet (part of Amgen)
  • Millennium Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Mochida Pharmaceutical
  • Molecular Partners
  • MorphoSys
  • Nektar Therapeutics
  • Neopharm Group
  • NeoStem
  • NeuralStem
  • Nippon Kayaku
  • Novartis
  • Novo Nordisk
  • Nuron Biotech
  • NuVasive
  • Ocata Therapeutics (formerly Advanced Cell Technology)
  • OncoSec Medical
  • OPKO Health
  • Oramed Pharmaceuticals
  • Organogenesis
  • Organovo
  • Orthofix
  • Osiris Therapeutics
  • PeriphaGen Holdings
  • Perrigo Company
  • Pfizer
  • Pieris
  • Piramal Group
  • Progenics Pharmaceuticals
  • Prolor Biotech (part of OPKO Health)
  • Rani Therapeutics
  • ratiopharm (part of Teva)
  • Redwood Bioscience
  • Regeneron Pharmaceuticals
  • Reliance Life Sciences
  • ReNeuron
  • RIKEN [Japan]
  • Roche
  • Roche Glycart (part of Roche)
  • SAFC
  • Sandoz (part of Novartis)
  • Sanofi
  • Seattle Genetics
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech (part of Benda)
  • Shreya Life Sciences
  • SironRX Therapeutics
  • Skye Orthobiologics
  • Sorrento Therapeutics
  • Sotex PharmFirm
  • Spark Therapeutics
  • Spectrum Pharmaceuticals
  • Spirogen (part of AstraZeneca)
  • Stelis Biopharmaceuticals (part of Strides Arcolab)
  • Stem CentRx
  • StemCells
  • Stempeutics Research
  • Strativa Pharmaceuticals
  • Strides Arcolab
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (Sobi)
  • Symphogen
  • Synthon
  • Synthon Biopharmaceuticals BV (part of Synthon)
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries
  • Thermalin Diabetes
  • TiGenix
  • TRION Pharma
  • UCB
  • UniQure
  • USV
  • VBL Therapeutics
  • Vericel Corporation
  • Versartis
  • viDA Therapeutics
  • Viventia Biotechnologies Inc
  • VX Pharma
  • Wyeth (part of Pfizer)
  • Xencor
  • Xeris Pharmaceuticals
  • Zydus Cadila
  • List of Organizations Mentioned in the Report
  • Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
  • Babraham Institute
  • Centers for Disease Prevention and Control (CDC) [US]
  • Children's Hospital of Philadelphia (CHOP)
  • China Food and Drug Administration (CFDA)
  • Duke University
  • Duke University Hospital
  • EMA's Committee for Medicinal Products for Human Use (CHMP)
  • European Commission
  • European Medicines Agency (EMA)
  • Food and Drug Administration (FDA) [US]
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
  • International Diabetes Federation (IDF)
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Moorfields Eye Hospital [UK]
  • National Cancer Institute (NCI) [US]
  • National Health Service (NHS) [UK]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
  • Royal Institute of Technology [Sweden]
  • Russian Ministry of Healthcare (Minzdrav)
  • Scottish Medicines Consortium (SMC)
  • Stanford University
  • Swiss Federal Institute of Technology
  • Tianjin International Joint Academy of Bio-medicine
  • University of California, San Francisco (UCSF)
  • University of Chicago
  • University of Toronto
  • World Bank Group
  • World Cancer Research Fund (WCRF)
  • World Health Organization (WHO)
  • Yale School of Medicine)